Vir Biotechnology Partnership: Bold $1.88B Gilead Deal
Vir Biotechnology partnership with Gilead is worth up to $1.88B, with $90M upfront, for three solid-tumour T-cell engagers. Terms, science and risks.
Vir Biotechnology partnership with Gilead is worth up to $1.88B, with $90M upfront, for three solid-tumour T-cell engagers. Terms, science and risks.